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Summary
Amphotropic recombinant retroviruses were generated carrying sequences encoding human
adenosine deaminase (ADA). Transcription of the human ADA gene was under control of a
hybrid long terminal repeat in which the enhancer from the Molony murine leukemia virus
was replaced by an enhancer from the 17101 host-range mutant of polyoma virus. Hemopoietic
stem cells in murine bone marrow were infected with this virus under defined culture conditions.
As a result, 59% ofday-12 colony forming unit spleen (CFU-S) stem cells became infected without
any in vitro selection. Infected CFU-S were shown to express human ADA before transplantation
and this expression sustained upon in vivo maturation. Mice transplanted with infected bone
marrow exhibited humanADA expression in lymphoid, myeloid, and erythroid cell types. Moreover,
human ADA expression persisted in secondary and tertiary transplanted recipients showing that
human ADAexpressing cells were derived from pluripotent stem cells. These characteristics of
our amphotropic viruses make them promising tools in gene therapy protocols for the treatment
of severe combined immunodeficiency caused by ADA deficiency. In this respect it is also relevant
that the viral vector that served as backbone for the ADA vector was previously shown to be
nonleukemogenic.
D eficiency of adenosine deaminase (ADA;' adenosine
aminohydrolase, EC 3.5.4.4) activity is associated with
an autosomally inherited form of severe combined immuno-
deficiency (ADA-SCID) disease (1, 2). It has been suggested
that this form of SCID is caused by a defect in T and B cell
differentiation due to the accumulation of adenine nucleo-
sides as the result of the absence of functional ADA (2). The
cloning of sequences encoding human ADA (hADA) (3-5)
and the recessive nature of the disease allowed studies aimed
at the development of gene therapy protocols for ADA-SCID
patients (6-9). The objective of such a gene therapy protocol
would be to repopulate the lymphoid blood cell compart-
ment of the patients by introducing a functional ADA gene
into their hemopoietic stem cells (HSC).
To date, successful transfer of foreign genes into pluripo-
tent hemopoietic stem cells (PHSC) has been performed using
'Abbreviations used in this paper. ADA, adenosine deaminase; BMC,
bone marrow cells; CFU-S, CFU-spleen; dCF, deoxycoformycin; EC,
embryonal carcinoma; hADA, human ADA; HSC, hemopoietic stem
cells; LTR, long terminal repeat; Mo-MuLV, Moloney murine leu-
kemia virus; PHSC, pluripotent HSC; Xyl-A, xylofuranosyl-adenine.
recombinant ecotropic retroviruses with a host rangelimited
to mice (e.g., 10). Studies with amphotropic viruses, which
can also infect human cells, are few (7) and did not provide
evidence for gene transfer into PHSC. Another limitation
of previous studies has been that several vectors appeared to
be incapable ofdirecting sustained expression in hemopoietic
cells in vivo. It has been reported, for example, that a number
of vectors that are active in mature hemopoietic cells are not
expressed in blood cells of animals transplanted with infected
hemopoietic stem cells (6, 7, 11). Likewise, a great number
ofvectors are transcriptionally inactive in undifferentiated em-
bryonal carcinoma (EC) cells, and it has been suggested that
an analogy exists in the mechanisms responsible for the ex-
pression block in EC cells and in hemopoietic cells in vivo
(7, 12, 13). To overcome this repression phenomenon in the
hemopoietic system, most investigators introduced additional
promoters within the viral transcription unit (8, 9, 12, 14,
15). Although this has led to some progress in the expres-
sion patterns, the outcome of such alterations seems unpre-
dictable, which is witnessed by the fact that a number of
strong promoters that act constitutively in various cell types
were inactivated when introduced into HSC as part of
retrovirus vectors (6, 9, 11, 16).
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(LTR) of retroviruses are known to be responsible for ex-
pression specificity (17), our efforts to obtain expression in
hemopoietic cells in vivo have been directed towards altera-
tions of this element. We have recently described (13) the
construction of a recombinant retrovirus in which a marker
gene wasplaced under thetranscriptional control of ahybrid
LTR designated OMo+PyF101 (18) . In this construct the
enhancer from Moloneymurine leukemia virus(Mo-MuLV)
was replaced by the enhancer of a mutant polyoma virus
(PyF101) that was selected to grow in EC cells. The vector
exhibiteduseful expression patterns sinceit could direct gene
expression in EC cells as well as in HSC. Moreover, upon
transplantation of infected bone marrow cells (BMC) into
lethally irradiated mice, virus expression was sustained in
hemopoieticcells of the engrafted recipients (13). Its charac-
teristics render the OMo+PyF101-LTR quite useful for the
design of vectors to be employed in future gene therapy pro-
tocols. An additional advantageofsuch vectorswouldbe that
(incontrast to Mo-MuLVbased vectors) they arederivedfrom
a nonpathogenic retrovirus, sinceDavis et al. (19) have shown
that the leukemogenic potential of Mo-MuLV is abolished
when its LTR is replaced by the AMo+PyF101-LTR. We
have therefore setout to constructvectorsin which sequences
encoding human ADA are under the transcriptional control
of the AMo+PyF101-LTR. This paperdescribesthe construc-
tion of such a virus and its capacity to efficiently infect and
expressin cell types relevant forfuture gene therapypurposes.
In this respect it is ofimportance that thevirus used in these
studies has an amphotropic host range, which permits infec-
tion of human cells as well.
Materials and Methods
Vector Construction.
￿
ThepLgAL(AMo+PyF101)vector carries a
1.9-kb SstII (blunt)-C1al ADA cDNA containing fragment (1.4-
kb SstII fragment from pAMG1 [20] followed by 478 by of Mo-
MuLV sequencesfrom a Hpal to aC1aI site encompassing nucleo-
tides 7198 to 7676 [21]) located 3' from Mo-MuLV sequences
stretching from the 5' LTR and including the first 420 nt of the
gag gene (an Ncol (blunt)-EcoRl (blunt) fragment derived from
pN2 [22], akind gift from R. Hoeben, Leiden University). Down-
stream from the ADA sequences the vector carries the OMo+
PyF101-LTR (a C1aI-KpnI fragment from ApMLVC/R/B(+Py-
F101) [18])followed by cellular DNAoriginally isolated as sequences
flanking aprovirus (a Kpnl-EcoRl fragment from pZIPneoSV(X)1
[23]). For propagation in Escherichia coli the retrovirus sequences
were cloned into pBR322 (EcoRI-Sall (blunt)).
Vine Production andCell Culture
￿
NIH/3T3, ¢CRE andOCRIP
(24;kindly supplied by theauthors) cell lines were routinelymain-
tained in high glucose (4.5 g/1) a-modified essentialmedium, sup-
plementedwith 10%heat-inactivated FCS(Seromed, Berlin, FRG),
100 ug/mlstreptomycin (Gist-Brocades, Delft, TheNetherlands),
and 100 U/ml penicillin (Gist-Brocades).
Recombinant virus-producing cell lines were generatedby trans-
fection of 20 hg of plasmid DNA onto OCRE cells using the
calcium-phosphate technique(25) as modified by Chen andOkayama
(26). 48 h later the cellswere selected for ADA overerpression by
splitting them into medium containing 4 p.M xylofuranosyl-adenine
(Xyl-A)and 10 nM of thespecific ADA-inhibitordeoxycoformycin
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(dCF) (27), kind gifts from Drs. N.R. Lomax (Drug Synthesis
and Chemistry Branch, NCI, Bethesda, MD) and R.E. Kellems
(Baylor College of Medicine, Houston, Texas), respectively. After
10 dof selectionresistant clones were pooled andexpanded. Filtered
(0.45 pm pore size) supernatant culture medium from these cells
was used to infect +SCRIP cells. Upon Xyl-A/dCF selection, in-
dividual virus-producing clones were isolated and expanded.
Amphotropicvirus-producing cell lines were initially assayed for
virus production by infecting NIH/3T3 cells that hadbeen plated
105 cells/60-mm dish in medium containing 4 14g/ml polybrene
(Sigma Chemical Co., St. Louis, MO) 24 hbefore infection. After
2 h of infection with 2 ml of culture supernatant from the pro-
ducer cells, fresh culture medium was added andthe cells were al-
lowed to grow for four more days. Zymogram analysis of these
infected cells allowed serniquantitative evaluation of virustiters by
comparingtheintensity of thehumanandtheendogenous murine
ADAactivities.Titers were determined quantitatively on thebasis
of Xyl-A/dCF resistance ofinfected NIH/3T3 cells. NIH/3T3 cells
plated as before were infected for 2 hwith serial diluted virus su-
pernatant. After 24 h thecells were reseeded 1:40 in medium con-
taining 4 uM Xyl-A and 1 nM dCF. Upon 10 d of selection resis-
tant colonies were scored.
Thepresence ofreplication-competent viruswastested by marker
rescue. NIH/3T3 cells infected with ZIPneoSV(X)1 virus (23) were
seeded 105 cells/60-mm dish in medium containing 4 ttg/ml poly-
brene. 24 h later thesecells were infected with cell-culture super-
natant or murine serum. Fresh culture medium was added after
2 h andthe cells were passaged for 7 d withoutanyselection. The
culture medium was refreshed and supernatant was harvested 2 h
later. The filtered supernatant was used to infect NIH/3T3 cells.
24 hlaterthemedium wasreplacedby medium containing 1 mg/ml
G418 (Geneticin; Gibco, Paisley, Scotland). After 10 dof selection
resistantcolonies were scored. The sensitivity ofthis assaywasde-
termined by mixing thevirus supernatant with knownconcentra-
tionsofamphotropic replication-competent 4070Avirus. From these
experiments we deduced that the presence of one focus forming
unit/ml, as determined by S*L- assay (28), could reproducibly be
detected in this assay.
DNA andEnzyme Analyses.
￿
Hemopoietic cells were isolated
from various tissues for the analysis of proviral integration and
human ADAexpression. Spleen colonies andtotalspleen or thymus
samples were flash-frozen in liquid Nz directly after dissection. Pe-
ripheralbloodsamples were takenby puncturing theorbitalplexus.
PBL were purified from these samples by erythrocyte lysis in 155
mM NH4C1, 12 mM NaHC05, 89 pM EDTA. B cells were ob-
tained by dispersing splenic tissue through nylon mesh and subse-
quentstimulation with LPS for4d, upon which mononuclear cells
were isolated by Ficoll (LSM; Organon Teknika, Durham, NC)
density-gradient separation, resulting in a>99% pure Bcell popu-
lation (29). Splenic high density nucleated cells were obtained by
Ficoll separation and subsequent erythrocyte lysis ofpelleted cells.
BMC were harvested from the femora and tibiae. Most samples
were stored at -80°C until analysis.
High molecular weight DNAforSouthern analysis wasisolated
as describedpreviously (30). Genomic DNA (10h.g) was digested
with the appropriate restriction enzymes and subjected to elec-
trophoresis in a 0.6 or 0.7% agarose gel. The DNA was trans-
ferred to a membrane and hybridized with either the 31P-labeled
NcoI-EcoRI hADA-cDNA fragment from pAMG1 (20), or the
Xbal PolyomaF101 enhancer-containing fragment from ApMLV
C/R/B(+PyF101) (18) according to standard procedures.
Isozyme-specific ADAactivity was detected in lysates ofin vitro
cultured cells, murine hemopoietic tissues, dissected spleen colo-
Infection of Pluripotent Hemopoietic Stem Cells by Amphotropic Virusnies, orblood samples by zymogram analysis as describedby Meera
Khan et al. (31).
Murine Bone Marrow Culture and Transplants.
￿
BMC were ob-
tained by flushing the femora and tibiae of 7-wk-old BCBA
(C57BL/KaLwRij x CBA/BrARij)F 1 mice . The bone marrow
was enriched for hemopoietic stem cells on a metrizamide density
gradient (sp.gr. <1.08 g/cm3) (32) . Using this procedure we rou-
tinely find 30-80% of day 12 CFU-S in the low density fraction .
10 5 low density BMC/ml were cocultivated for 72 h with a 70%
confluent irradiated (20 Gy) monolayer of virus-producing cells in
the standard medium described above under "Virus Production and
Cell Culture," supplemented with human HIrla (Biogen, Geneve,
Switzerland), murine rl1r3, and 0.4 l~g/ml polybrene. When a pre-
selection for ADA overexpression was to be performed, the cocul-
tivation period was reduced to 48 h, during which the cells were
pretreated with 20 nM dCF . Subsequently, the nonadherent cells
were removed and cultured for an additional 24 h under serum-free
conditions, either with or without the addition of 4 1AM Xyl-A
and various concentrations of dCF. The cells were intravenously
injected into syngeneic 12-16-wk-old lethally irradiated (8.5 Gy)
recipient mice . The equivalent of 2 x 10^ and 105 unselected or
105 and 106 selected BMC was injected for the analysis of in-
dividual day 12 CFU-S-derived spleen colonies . For long-term ex-
pression studies mice were repopulated with the equivalent of 106
or 5 x 106 unselected BMC, including the adherent cell layer.
Results
Production of Recombinant hADA Viruses.
￿
In previous ex-
periments we have successfully used theAMo+PyF101-LTR
to overcome the expression block encountered by retroviruses
in the hemopoietic system (13) . Based on this experience we
constructed the retroviral vectorpLgAL(AMo+PyF101) (Fig.
1) . This vector carries the human ADA cDNA downstream
from a Mo-MuLVLTR, whereas the AMo+PyF101-LTR was
used as a 3'LTR. Due to the fact that U3 in the resulting
retroviral genome will be derived from the 3'LTR, the alter-
ation in the U3 region oftheAIM+PyF101-LTR is expected
to be present in both LTRs of the resulting recombinant
retroviruses . In addition, a fragment from Mo-MuLV that
stretches from the YLTR up to position 420 of the gag gene
was included 5' of the hADA cDNA gene .
tiGCRE ecotropic packaging cells transfected with
pLgAL(OMo+PyF101) were selected for ADA overexpres-
sion with Xyl-A and dCF (27) . Zymogram analysis of the
resistant cells revealed the presence ofnew isozymes with elec-
Figure 1 .
￿
Structure of the retroviral vector pLgAL(AMo+PyF101) .
The open box represents the human ADA cDNA . The hatched and
crossed boxes indicate the Mo-MuLV and PyFlOl-enhancer sequences
within the viral LTRs, respectively. The Mo-MuLV gag-sequences, as
well as the positions of the TATA-box (open circle), the CAATbox
(closed rectangle), and G/C motif (open rectangle) in the viral promoter
are indicated. The sites for transcription initiation (arrow), polyadenyl-
ation [(A)n], and relevant restriction enzymes are also shown.
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Figure 2 .
￿
Southern analysis of NIH/3T3 clones infected with
POC-1 virus. The structure of the LgAL(AMo+Py101) provirus in
the genome of infected cells is shown in a schematic drawing.
Genomic DNA (10 Ag) from OCRIP cells (lane 1) and two indepen-
dent NIH/3T3 clones infected with POC-1 virus (lanes 2 and 3) was
digested with Sstl (A) or Nhel (B) and fractionated on a 0.7%
agarose gel . The Southern blots shown in A and B were hybridized
with a hADA cDNA probe and a PyF101 enhancer probe, respectively .
The positions ofDNA molecular weight markers are indicated .
trophoretic mobilities identical to those of the human ADA
isozymes . Culture supernatant of these cells was used to in-
fect OCRIP amphotropic packaging cells. Upon selection with
Xyl-A/dCF, individual resistant clones were expanded . Virus
production from these clones was first tested by analyzing
the presence of human ADA activity in NIH/3T3 cells in-
fected with viral supernatant . We interpreted the relative in-
tensity of human ADA activity as compared with the en-
dogenous murine activity to be due to variations in the virus
titers issuing from the OCRIP clones. The clone showing
the highest virus production by this criterium was designated
POC-1 and further analyzed .
Since the provirus in the POC-1 cell line has undergone
one round ofreplication we expected theU3 regions in both
proviral LTRs to be derived from the YLTR of the shuttle
vector. The provirus in POC-1 should therefore carry the
PyF101 enhancer in both the 5' and the 3'LTR. The same
proviral structure is expected in cells that are infected with
virus supernatant ofPOC-1 . To test these predictions, DNA
from two individual NIH/3T3 cell lines that were infected
withPOC-1 virus supernatant was subjected to Southern blot
analysis. Genomic DNA was digested with restriction en-zymes that cut once within the LTR at either side of the
inserted PyF101-enhancer (NheI and Sstl, respectively). When
probed with the PyF101-enhancer (Fig. 2 B), the lanes con-
taining NheI-digested DNA from both infected target lines
revealed a fragment identical in size to the SstI-digested proviral
fragment hybridizing to the ADA cDNA (Fig. 2 A). This
proves that the PyF101-enhancer is indeed present in both
LTRs. The additional fragments hybridizing to the PyF101-
enhancer probe represent flanking genomic sequences.
A virus titer of the POC-1 supernatant was determined
by selection ofNIH/3T3 cellsinfected with it for Xyl-A/dCF
resistance and was shown to be 4.4 x 103 CFU/ml. This
rather low value is probably due to the fact that it relies on
the functional overexpression of human over murine ADA.
Such measurements usually result in titers lower than those
obtained by means of dominant selectable markers (8). This
notion is supported by our observation that the infection of 2
x 105 NIH/3T3 cells with 2 ml of virus supernatant resulted
in a cell population exhibiting similar levels of human and
murine ADA activity (not shown). Cell lines derived from
individual infected cells always contained an amount of human
ADA equal or less than that of the endogenous enzyme.
This suggests that in our mass-infection experiments most
NIH/3T3 cells became infected, which would require a mul-
tiplicity of infection that is -20 times higher then the titer
measured as Xyl-A/dCFR CFU/ml. The absence of replica-
tion-competent viruses in the supernatant of the POC-1 cell
line was demonstrated by a marker-rescue assay (see Materials
and Methods). The amphotropic host range of our ADA virus
was confirmed by successful restoration of the enzyme defect
in a lymphoblastoid cell line derived from an ADA - SCID
patient upon cocultivation with POC-1 cells (not shown).
Integration and Expression ofLgAL(dMo+PyF101) in Mu-
rine Hemopoietic Stern Cells and their Mature Progeny. We set
out by studying integration and expression in the class of
hemopoietic stem cells that can clonally grow out to form
macroscopic colonies on the spleen 12 d after their injection
into lethally irradiated recipients (day 12 CFU-S). To infect
day 12 CFU-S with LgAL(AMo+PyF101) we cocultivated
murine low-density bone marrow cells for 48 h with an ir-
radiated monolayer of POC-1 cells. To study the relation be-
tween hADA expression in the infected CFU-S (before trans-
plantation) and in their mature progeny present in day 12
spleen colonies, we adapted the Xyl-A/dCF selection proce-
dure to select for ADA-overexpressing bone marrow cells.
After cocultivation, the nonadherent cells were collected from
the irradiated monolayer and cultured for another 24 h under
serum-free conditions either with or without 4 p,M Xyl-A
and various concentrations of dCF. Lethally irradiated re-
cipients were injected with these bone marrow cells and 12 d
later the numbers of spleen colonies were scored. Spleen colo-
nies were dissected and zymogram analysis revealed 7% of
them to express the hADA gene when no preselection was
performed.
As can be seen in Fig. 3, the preselection for ADA overex-
pression resulted in a [dCF]-dependent decrease in day 12
CFU-S survival, whereas the frequency ofhADA-expressing
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￿
Day 12 CFU-S survival and human ADA expression in
day 12 CPU-S-derived spleen colonies upon infection and preselec-
tion of murine bone marrow. The selection was performed for 24 h
using a combination of 4 pM Xyl-A and 0.1, 0.5, 1.0, 2.0, 6.0, 8.0,
or 10.0 nM dCF, respectively. The percentage day 12 CPU-S survival
is given as compared with the CFU-S survival without preselection
(i.e., bone marrow cultured under identical conditions without the
addition of Xyl-A and dCF). The frequency of hADA-expressing
spleen colonies was assessed by zymogram analysis on individually
dissected spleen colonies. The percentage hADA-expressing day 12
spleen colonies at 4 pM Xyl-A + 0.1 nM dCF is not given since an
insufficient number of individual spleen colonies could be analysed (at
this stringency 0 of 8 colonies tested expressed hADA).
spleen colonies increased. At 2 nM dCF, the CFU-S survival
(7.6%) closely resembled the infection efficiency (7%) and
at this stringency the percentageof hADAexpressing spleen
colonies rose to 73%. The procedure did not result in a 100%
expression frequency at any of the stringencies used. We as-
sume that this is brought about by a fraction of day 12
CFU-S that remained in Go during the period of infection
and preselection, and consequently were resistent to retroviral
infection and to the selection procedure.
We have also shown that this 24-h selection with Xyl-
A/dCF could only be achieved in the absence of the virus-
producing fibroblasts. This evidence came from an experi-
ment in which bone marrow was cocultivated for 2 d with
an irradiated NIH/3T3 cell line that did not produce any
virus, but carried a copy of the LgAL(AMo+PyF101) virus.
The Xyl-A/dCF selection was performed at 20 nM dCF, but
this time in the presence of the fibroblast cells. Upon injec-
tion into irradiated recipients the number of day 12 spleen
colonies was shown not to be reduced, and as expected, none
of 25 spleen colonies tested expressed human ADA (data not
shown). Apparently, the irradiated fibroblasts are able to
detoxify the culture medium of Xyl-A.
The fact that ADA preselection resulted in a [dCF]-
dependent increase in the number ofhADAexpressing spleen
colonies proves that the stem cellswere overexpressing ADA
before transplantation and subsequently sustained this expres-
sion upon in vivo differentiation into the more mature cell
types present in day 12 spleen colonies.
SustainedExpression ofLgAL(dMo + PyF101) in the Murine
Hemopoietic System. To study the expression of human
ADA in cells derived from infected hemopoietic cells with
a more extensive self-renewing capacity than the day 12 CPU-S,
mice were transplanted with 106 cocultured BMC to allow
Infection of Pluripotent Hemopoietic Stem Cells by Amphotropic Virusa complete regeneration of the hemopoietic system. To study
whether the Xyl-A/dCF selection procedure could also be
applied to hemopoietic stem cells with regenerating capacity,
a preselection at various stringencies was included in the pro-
cedure . 30 d after transplantation human ADA expression
was analyzed in peripheralblood cells . All mice tested (23/23)
expressed the human ADA gene. However, a clear [dCFJ-
dependent decrease in day 30 survival was observed . As can
be seen in Table 1, all mice that received bonemarrow that
was preselected with 4fLM Xyl-A and 0.1 nM dCF survived
the radiation . Strikingly, an increased selection stringency of
1 nMdCF resulted in the abolishment ofradiation-protective
capacity of the bone marrow, whereas the CFU-S-survival
was not significantly affected . These data indicated to us that
repopulating hemopoietic stem cells are extremely sensitive
to the Xyl-A/dCF selection procedure . Complete radiation
protection could not be obtained upon transplantation ofbone
marrow preselected at dCF concentrations above 0.1 nM and
at this stringency no increase in the percentage of human
ADAexpressing day 12 spleen colonies was observed (see Fig.
3) . From this,we concluded that the applied preselection did
not result in the survival ofenough infected hemopoietic stem
cells exhibiting radioprotective capacities .
In a further attempt to increase the efficiency ofgene transfer
we prolonged the cocultivation period from 48 to 72 h . Bone
marrow was enriched for hemopoietic stem cellson a metriza-
mide density gradient (32) and low density cells representing
25% of the total marrow aspirate were cocultivated with
POC-1 cells . The toxicity of the complete procedure was as-
sessed by determining the recovery ofday 12CFU-S . Normal
bone marrow contained 228 ± 12 SEM day 12 CFU-S per
Table 1 .
￿
Stem Cell Parameters and hADA Expression after
Cocultivation, ADA Preselection, and Transplantation of
Murine Bone Marrow
* Number of viable day 12 CFU-S present in 10 6 injected bone mar-
row cells, given as mean ± SEM .
t 30 d survival following 8.5 Gy irradiation and transplantation with
the equivalent of 106 BMC is given as the number of surviving mice
per total tested .
S hADA expression was tested at day 30 in peripheral blood cells of
all surviving animals and is given as the number of hADA-
expressing mice per total tested.
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106 cells. After stem cell enrichment and 72-h cocultivation,
the recovery of day 12 CFU-S was 25% (56 ± 6 SEM/1(16
normal bone marrow equivalents) . Zymogram analysis demon-
strated that 59% of the day 12 spleen colonies expressed the
human ADA gene (not shown), indicating that the 3 d of
cocultivation resulted in a significantly higher infection
efficiency than 2 d (7%) . In vivo infection ofCFU-S could
be excluded by control experiments in which irradiated POC-1
virus-producing cells were mixed with normal bonemarrow
shortly before transplantation . The resulting spleen colonies
always remained negative for hADA-expression (37 colonies
tested) .
10 mice transplanted with 106 cocultivated bone marrow
cells were killed and analyzed forhADA expression 34 d after
transplantation . In Fig. 4 the results are summarized . All mice
expressed hADA in erythrocytes and spleen cells. In addi-
tion, five mice showed humanADA expression in PBL and/or
thymus cells, proving that the infected hemopoietic stem cells
gave rise tohADAexpressing cells of erythroid and lymphoid
lineages. To study the self-renewing capacity ofthe stem cells
responsible for the observed hADA expression pattern, bone
Figure 4 .
￿
Human ADA expression in hemopoietic tissues of mice
transplanted with LgAL(GMo+PyF101)-infected bone marrow. The
top panel gives the results from zymogram analyses on RBC, PBL,
spleen, and thymus from 10 mice killed 34 d after transplantation
with 106 cocultured bone marrow cells. Examples ofhADA " zymo-
grams from each tissue are shown in the bottom panel . The positions
of human and mouse ADA are indicated.
Selection
stringency
Day 12
CFU-S'
30-d
radiation
protection=
hADA
expression
in PBCS
No selection 123 ± 14 10/10 10/10
4 PM Xyl-A +
0 .1 nM dCF 29 ± 6 8/8 8/8
4 pM Xyl-A +
0.5 nM dCF 28 ± 4 5/8 5/5
4 p,M Xyl-A +
1.0 nM dCF 25 ± 8 0/7marrow was harvested from the four mice that showedhADA
expression in PBL (mice 4, 5, 9, and 10) and transplanted
into secondary irradiated recipients . These animals received
either 10 5 or 5 x 106 BMC and were killed at day 15 or 34,
respectively, for hADA expression analysis. At day 15, hADA
expression was analyzed in peripheral RBC, bone marrow,
and spleen . At day 34 PBL and thymus cells were included
in the analyses, as well as splenicB cells, obtained by stimula-
tion with LPS, and splenic high density nucleated cells of
mainly myeloid origin . Some of the secondary recipients from
mice 4, 5, and 9 exhibited hADA expression limited to the
erythroid lineage. On the other hand, transplantation ofbone
marrow from mouse 10 into secondary recipients resulted in
a persistence ofhADA expression in lymphoid, myeloid, and
erythroid lineages . Zymograms of organs from representa-
tive mice killed at day 15 and 34 are shown in Fig. 5 . hADA
expression was observed in all tissues examined, except in
thymus cells. The latter could have been caused by the fact
that thymus tissue has extremely high endogenous ADA levels,
which hinders the detection of hADA in this organ . Not
unexpectedly, the observed expression also persisted upon re-
transplantation into tertiary recipients (not shown) .
Lineage-specific integration analysis was performed on DNA
extracted from tissues from mouse 10 and its secondary
recipients by digestion with EcoRI, which does not cut in
the provirus, and Southern analysis. As can be concluded from
Fig . 6, hADA-expressing hemopoietic tissues from all sec-
ondary recipient mice tested exhibit one major proviral in-
tegration site, indicating that the amphotropic hADA virus
infected at least one pluripotent hemopoietic stem cell . In
addition, our data provide evidence against in vivo reinfec-
tion due to the generation of replication-competent virus .
The absence of replication-competent virus in the serum of
all secondary transplanted animals was further confirmed via
a marker-rescue assay, as described in Materials and Methods .
Figure 5 .
￿
Zymograms of hemopoietic tissues from mouse 10 and
two representative hADA-expressing animals killed at day 15 or 34.
The positions of the human and murine isozymes are indicated. Spl,
spleen ; BM, bone marrow ; B, splenic B cells; Sp1M, splenic high-
density nucleated cells (myeloid) .
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Discussion
In our efforts to overcome the expression block encoun-
tered by retroviral vectors in the hemopoietic system, we have
chosen to alter the enhancer sequences present in the retroviral
LTR . Previously we have described sustained expression of
the neon gene in murine hemopoietic cells . This was accom-
plished using a replication-defective retrovrus in which the
Mo-MuLV enhancer sequences present in the LTR were
replaced by the enhancer element from the polyoma host-
range mutant F101 (13) . An extra advantage of this altera-
tion in the LTR is offered by the fact that it renders Mo-
MuLV nonpathogenic . Here we describe the construction of
a retroviral vector in which thehuman ADAcDNA is placed
under transcriptional control of this AMo+PyF101-LTR .
With this construct a cell line designatedPOC-1 was gener-
ated that produced amphotropic replication-defective retro-
viruses carrying thehADA gene. Subsequently, experiments
were performed to test the efficacy of this virus in future gene
therapy protocols for the treatment ofADA-SCID disease.
Figure 6 .
￿
Southern analysis of DNA isolated from hemopoietic
cells from primary recipient mouse 10 and secondary recipients trans-
planted with bone marrow from mouse 10. The DNA was digested
with EcoRl, which does not cut in the provirus, separated on a
0.6% agarose gel, blotted to a membrane, and hybridized to the
ADA cDNA probe . Lane 1, spleen from mouse 10 ; lanes 2-3, spleens
from two individual secondary recipients killed 15 d after transplanta-
tion; lanes 4-6, B cells from three individual secondary recipients
killed at day 34 after transplantation. The positions ofDNA molec-
ular weight markers are indicated. The 11.5- and 2.3-kb bands
hybridizing to the ADA probe represent crosshybridization to endog-
enous murine ADA sequences. In all secondary recipients a 7.5-kb
provirus integration fragment, indicated by the arrow, is clearly
present .
Infection of Pluripotent Hemopoietic Stem Cells by Amphotropic VirusUsing POC-1-derived viruses we achieved efficient mod-
ification of the murine hemopoietic system in vivo. We set
out to measure infection and expression efficiency in CFU-S.
It appeared that a 48-h cocultivation of murine bonemarrow
with the virus-producing cells resulted in only 7% of the
day 12 CFU-S being infected. A considerable increase in in-
fection efficiency (up to 59%) was achieved by a prolonga-
tion of the coculture period to 72 h . We conclude from these
data that most CFU-S became susceptible to retrovirus in-
fection at the third day of stimulation by IIs1 and IL3, pos-
sibly due to the fact that more stem cells have left Go at that
point . The POC-1 cell line did not exert a significant toxic
effect on the day 12CFU-S during this cocultivation period,
and in contrast to previous reports by other investigators (11,
33), a pretreatment of bone marrow donor mice using 5-
fluorouracil was not required for the high infection efficiency.
The latter is of importance for future gene therapy proce-
dures where such a taxing pretreatment is best avoided. Ex-
pression ofhADA in infected day 12 CFU-S and their progeny
was quantified by adapting the Xyl-A/dCF selection proce-
dure (27). Whereas recently Lim et al . (33) reported that
this selection procedure requires exposure of cells for 7-10 d,
we show here that a selection for only 1 d is sufficient to
kill uninfected day 12 CFU-S under serum-free conditions
in the absence of fibroblast cells . A preselection of infected
bone marrow using Xyl-A/dCF resulted in a clear [dCF]-
dependent increase in the frequency ofhADAexpressing spleen
colonies. This proves that infectedCFU-S were overexpressing
ADA before transplantation and subsequently sustained this
expressionupon in vivo differentiation . We envisage that this
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